PFS Valid Surrogate Endpoint for OS in Untreated DLBCL

New data support PFS as a surrogate endpoint for OS in future trials evaluating chemoimmunotherapy in DLBCL.

Source: CancerNetwork - August 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news